Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Income from Continuing Operations (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Income from Continuing Operations for 15 consecutive years, with 7215000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 38.78% to 7215000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 45856000.0 through Dec 2025, down 1.02% year-over-year, with the annual reading at 45856000.0 for FY2025, 1.02% down from the prior year.
  • Income from Continuing Operations hit 7215000.0 in Q4 2025 for Cardiff Oncology, up from 11258000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5442000.0 in Q1 2021 to a low of 13942000.0 in Q2 2025.
  • Historically, Income from Continuing Operations has averaged 10114400.0 across 5 years, with a median of 10225000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: crashed 103.49% in 2022 and later surged 38.78% in 2025.
  • Year by year, Income from Continuing Operations stood at 9526000.0 in 2021, then increased by 1.41% to 9392000.0 in 2022, then rose by 0.72% to 9324000.0 in 2023, then decreased by 26.39% to 11785000.0 in 2024, then soared by 38.78% to 7215000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CRDF at 7215000.0 in Q4 2025, 11258000.0 in Q3 2025, and 13942000.0 in Q2 2025.